Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin

Novo Nordisk’s phase III study of insulin icodec, a once-weekly treatment for type 2 diabetes, has concluded, and the company reports that its primary goal was achieved.

Photo: Novo Nordisk / PR

Novo Nordisk has concluded a phase III study, dubbed Onwards 2, of once-weekly insulin icodec, the company has announced in a Thursday press release.

The drug was compared to Novo’s long-acting insulin degludec, which is sold under brand name Tresiba and administered once daily. According to results, icodec is as good as degludec.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs